Leerink Partners Cuts Humana (NYSE:HUM) Price Target to $185.00

Humana (NYSE:HUM) had its price objective cut by Leerink Partners from $267.00 to $185.00 in a research note issued to investors on Thursday,MarketScreener reports. They currently have a market perform rating on the insurance provider’s stock.

A number of other brokerages have also recently issued reports on HUM. Morgan Stanley set a $146.00 price objective on shares of Humana in a report on Thursday. Guggenheim cut their price target on Humana from $312.00 to $252.00 and set a “buy” rating for the company in a research note on Thursday. Sanford C. Bernstein reissued an “outperform” rating and issued a $344.00 price objective on shares of Humana in a research note on Tuesday, January 6th. Evercore ISI dropped their target price on Humana from $260.00 to $180.00 in a report on Thursday. Finally, Royal Bank Of Canada downgraded Humana from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $322.00 to $189.00 in a report on Thursday. Seven research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $238.29.

Humana Stock Up 2.8%

Shares of NYSE:HUM opened at $183.92 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.02 and a current ratio of 2.00. Humana has a 52-week low of $169.61 and a 52-week high of $315.35. The business’s 50 day simple moving average is $244.65 and its two-hundred day simple moving average is $261.05. The firm has a market cap of $22.12 billion, a P/E ratio of 18.73, a PEG ratio of 2.04 and a beta of 0.44.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. During the same period in the prior year, the firm earned ($2.16) earnings per share. Humana’s revenue for the quarter was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, research analysts forecast that Humana will post 16.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Transamerica Financial Advisors LLC increased its position in shares of Humana by 36.1% during the 4th quarter. Transamerica Financial Advisors LLC now owns 490 shares of the insurance provider’s stock valued at $126,000 after purchasing an additional 130 shares during the last quarter. UMB Bank n.a. increased its holdings in Humana by 75.7% during the fourth quarter. UMB Bank n.a. now owns 1,304 shares of the insurance provider’s stock worth $334,000 after buying an additional 562 shares during the last quarter. Stifel Financial Corp raised its position in Humana by 14.4% in the fourth quarter. Stifel Financial Corp now owns 22,938 shares of the insurance provider’s stock worth $5,875,000 after acquiring an additional 2,879 shares during the period. Smartleaf Asset Management LLC raised its position in Humana by 41.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,995 shares of the insurance provider’s stock worth $517,000 after acquiring an additional 582 shares during the period. Finally, Bank of Nova Scotia boosted its stake in Humana by 366.8% in the fourth quarter. Bank of Nova Scotia now owns 360,793 shares of the insurance provider’s stock valued at $92,410,000 after acquiring an additional 283,505 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

More Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.